FDA accepts new drug application for ED topical cream

Article

FDA has accepted a new drug application for a topically applied alprostadil cream for the treatment of erectile dysfunction, according to NexMed, Inc., the drug’s developer.

FDA has accepted a new drug application for a topically applied alprostadil cream for the treatment of erectile dysfunction, according to NexMed, Inc., the drug’s developer.

The acceptance for review is an indication that FDA has determined that the filing is sufficient to complete a substantive review of the application, which customarily takes a minimum of 8 months, should the agency not require any additional studies or information, the company said.

Related Videos
Samuel L. Washington III, MD, answers a question during a Zoom video interview
blurred image of a clinic hallway
Dr. Kyle A. Richards in an interview with Urology Times
Expert on OAB
Experts on OAB
Expert on OAB
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
stethoscope on laptop keyboard
Related Content
© 2023 MJH Life Sciences

All rights reserved.